Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3
0
Authors
T. Mercadé
19 more
T. Mercadé
•
Roberto Pazo-Cid
17 more
•
Davide Melisi
Published
June 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Annals of Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Cancer Research
Gemcitabine
Show all topics
DOI
10.1016/j.annonc.2024.05.466
